Listen Now!

Business Talk 24-7

Skyland Trail

behavioral medicine

Beth Finnerty

Skyland Trail

A recent guest of mine on the Top Docs Radio show told me I needed to get to know about Skyland Trail, an Atlanta area inpatient/outpatient behavioral medicine center, well-known for its outcomes such that patients travel from across the US and abroad to receive care there.

I had the opportunity to sit down with President of Skyland Trail, Beth Finnerty, to learn about how their care professionals both rely upon evidence, as well as contributing to science, to guide their care.  I was pleased to receive an invitation to tour the beautiful facilities, which includes a newly-opened 30 bed residence and care center for young adults.

The Skyland trail website describes the facility this way, “Few things can be as overwhelming and frustrating as mental illness – or finding effective treatments. At Skyland Trail, we get it. Which is why we take a different approach to helping adults with mental health issues.

Located in Atlanta, Skyland Trail is a nationally recognized nonprofit mental health treatment organization serving adults ages 18 and older. 

We’re not a hospital or lock-down institution, we’re one of the nation’s top mental health treatment centers – a voluntary treatment community of clients finding new ways to overcome the limitations of their illness and reclaim their lives.

But success is built on a two-way commitment – we’re committed to our patients and we ask our patients to commit to our approach. Each client has to put in the time and effort needed to make real and sustainable progress.

As a long-term residential treatment facility, we’re serious about healing and we’re passionate about the community we serve.

As one of the best mental health treatment centers in the country, we’re focused on people with complex mental health issues, helping them understand that they are more than their diagnoses dictate – helping them grow, recover and reclaim their lives.

We treat adults ages 18 and older with a primary psychiatric diagnosis – a mood or thought disorder like bipolar illness, major depression, or schizophrenia, or an anxiety disorder. Most clients have co-occurring diagnoses including alcohol or substance abuse, borderline personality disorder, or secondary anxiety disorders. 

Because of our onsite primary care clinic, we can support those who have medical health needs in addition to psychiatric needs. 

While our clients are largely from Georgia and the southeast we have many clients from across the U.S. and a few from around the world.

We treat each individual, individually, tailoring an approach that includes a broad mix of evidence-based one-on-one and group therapies that help prepare our clients for reintegration into their lives.

Our holistic treatment model integrates strategies to help clients improve mental health, physical wellness, and relationships with family and friends.

Pharmacogenetic Testing

Pharmacogenetic Testing

This week I spoke with founder and CEO of Genelex, Howard Coleman to learn about pharmacogenetic testing, and the role it plays in patient outcomes and overall healthcare spend.  Pharmacogenetic testing involves obtaining a sample of DNA from the patient via a cheek swab or blood test and examining the genes associated with metabolizing medications.

With this information, a prescribing physician can know in advance that, “This patient is a poor metabolizer for Plavix, meaning they won’t activate the drug.  I need to order a different anticoagulant,” for example.  While there are numerous factors that come into play to determine how an individual’s body responds to a medication, or combination of medications, this data can help prescribing providers avoid readily-identifiable adverse drug events.

Adverse drug events occur in over 100,000 persons per year, with an average cost of ~$20,000+ per event per patient, with many resulting in serious illness, injury, or death.  The data obtained by this one-time test is valid for the life of the patient, allowing physicians and other providers the ability to incorporate the data into medication prescription decisions for the rest of their lives.

Recent changes in the law have placed requirements on advancing technologies that will enable more personalized delivery of healthcare to patients, going so far as to include outcomes in calculating rates of reimbursement.  Additionally, greater emphasis is being placed on “wellness” and prevention of illness/injury and moving away from a model aimed at “treating illness”, which created more of a “volume-based” focus.

Howard shared how Genelex evolved from a genetics lab providing forensic DNA testing to a precision medicine technology company in the early 2000’s.  Since then the company has been working to contribute to the body of evidence that continues to support the fact that certain groups of individuals are genetically inclined to respond in a fashion that is counter to what is desired and thus, at risk for a drug-related event.

Special Guest:

Howard Coleman, Founder/CEO, Genelex

pharmacogenetic testing